JP2024524461A5 - - Google Patents
Info
- Publication number
- JP2024524461A5 JP2024524461A5 JP2023580922A JP2023580922A JP2024524461A5 JP 2024524461 A5 JP2024524461 A5 JP 2024524461A5 JP 2023580922 A JP2023580922 A JP 2023580922A JP 2023580922 A JP2023580922 A JP 2023580922A JP 2024524461 A5 JP2024524461 A5 JP 2024524461A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- administered
- cancer
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217716P | 2021-07-01 | 2021-07-01 | |
| US63/217,716 | 2021-07-01 | ||
| PCT/US2022/035995 WO2023278860A1 (en) | 2021-07-01 | 2022-07-01 | Combination treatments in patients with advanced and/or metastatic trop-2 overexpressed cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524461A JP2024524461A (ja) | 2024-07-05 |
| JP2024524461A5 true JP2024524461A5 (enExample) | 2025-07-09 |
Family
ID=84692161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580922A Pending JP2024524461A (ja) | 2021-07-01 | 2022-07-01 | 進行性および／または転移性ｔｒｏｐ－２過剰発現ガンを有する治療困難患者における併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240139196A1 (enExample) |
| EP (1) | EP4362948A4 (enExample) |
| JP (1) | JP2024524461A (enExample) |
| KR (1) | KR20240029045A (enExample) |
| CN (1) | CN118215481A (enExample) |
| AU (1) | AU2022301309A1 (enExample) |
| CA (1) | CA3223467A1 (enExample) |
| IL (1) | IL309489A (enExample) |
| TW (1) | TW202317131A (enExample) |
| WO (1) | WO2023278860A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190092478A (ko) | 2016-12-05 | 2019-08-07 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TWI842274B (zh) * | 2022-12-15 | 2024-05-11 | 中化合成生技股份有限公司 | 曲拉西利之製備方法及曲拉西利之前驅體 |
| CN120591406A (zh) * | 2024-08-06 | 2025-09-05 | 中山大学附属第三医院 | Trop2抑制剂在制备诊断、预防和治疗结直肠癌骨髓转移的产品中的用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3969001A4 (en) * | 2019-05-15 | 2023-02-22 | Ayala Pharmaceuticals Inc. | BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS FOR THE TREATMENT OF NOTCH-ACTIVATED BREAST CANCER |
| TW202114684A (zh) * | 2019-06-18 | 2021-04-16 | 美商G1治療公司 | 增強癌症病患之抗腫瘤免疫之方法 |
-
2022
- 2022-07-01 EP EP22834324.0A patent/EP4362948A4/en active Pending
- 2022-07-01 WO PCT/US2022/035995 patent/WO2023278860A1/en not_active Ceased
- 2022-07-01 AU AU2022301309A patent/AU2022301309A1/en active Pending
- 2022-07-01 JP JP2023580922A patent/JP2024524461A/ja active Pending
- 2022-07-01 TW TW111124849A patent/TW202317131A/zh unknown
- 2022-07-01 CA CA3223467A patent/CA3223467A1/en active Pending
- 2022-07-01 KR KR1020247003327A patent/KR20240029045A/ko active Pending
- 2022-07-01 CN CN202280057773.6A patent/CN118215481A/zh active Pending
- 2022-07-01 IL IL309489A patent/IL309489A/en unknown
-
2023
- 2023-12-22 US US18/394,512 patent/US20240139196A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024524461A5 (enExample) | ||
| JP2025511399A5 (enExample) | ||
| JP2010514787A5 (enExample) | ||
| CN113750238A (zh) | 包含瓦尼替尼及抗癌剂之组合疗法 | |
| JP2011088921A (ja) | 血管形成及び／又は増加した血管透過性に関連する疾病の治療におけるゲムシタビンと、そして場合により電離放射と組み合わせたキナゾリン誘導体ｚｄ６４７４の使用 | |
| JP2022509262A5 (enExample) | ||
| JP2017516802A5 (enExample) | ||
| JP2019510785A5 (enExample) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2006513184A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2023548055A5 (enExample) | ||
| JP2018503610A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| Aisner et al. | Chemotherapy versus chemoimmunotherapy for small‐cell undifferentiated carcinoma of the lung | |
| RU2018126829A (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| JP2018513155A5 (enExample) | ||
| Ariel | Therapeutic effects of hydroxyurea. Experience with 118 patients with inoperable solid tumors | |
| Bokemeyer et al. | A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer | |
| JP2019038797A5 (enExample) | ||
| JP6116481B2 (ja) | 神経内分泌腫瘍を治療する方法 | |
| Neuhaus et al. | Successful treatment of intractable hiccups by oral application of lidocaine | |
| JP2023505687A5 (enExample) | ||
| Lise et al. | Adjuvant therapy for colorectal cancer: the EORTC experience and a review of the literature | |
| JP2024538719A5 (enExample) |